Pulmonx Corporation
LUNG · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $22 | $24 | $23 | $24 |
| % Growth | -9.9% | 5.9% | -5.2% | – |
| Cost of Goods Sold | $5 | $7 | $6 | $6 |
| Gross Profit | $16 | $17 | $16 | $18 |
| % Margin | 74.7% | 72.1% | 72.5% | 74% |
| R&D Expenses | $5 | $5 | $5 | $4 |
| G&A Expenses | $0 | $0 | $0 | $19 |
| SG&A Expenses | $26 | $27 | $26 | $27 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $8 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30 | $32 | $31 | $31 |
| Operating Income | -$14 | -$15 | -$15 | -$13 |
| % Margin | -66.9% | -62% | -64.6% | -56.5% |
| Other Income/Exp. Net | $1 | -$0 | $0 | $0 |
| Pre-Tax Income | -$14 | -$15 | -$14 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14 | -$15 | -$14 | -$13 |
| % Margin | -64.9% | -63.6% | -64.1% | -55.4% |
| EPS | -0.34 | -0.38 | -0.36 | -0.33 |
| % Growth | 10.5% | -5.6% | -9.1% | – |
| EPS Diluted | -0.34 | -0.38 | -0.36 | -0.33 |
| Weighted Avg Shares Out | 41 | 40 | 40 | 39 |
| Weighted Avg Shares Out Dil | 41 | 40 | 40 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$13 | -$14 | -$15 | -$13 |
| % Margin | -59.4% | -58.3% | -64.6% | -55.2% |